<DOC>
	<DOCNO>NCT00484991</DOCNO>
	<brief_summary>The Purpose study provide patient hyperphenylalaninemia ( HPA ) due Phenylketonuria ( PKU ) access sapropterin dihydrochloride collect information safety drug expand access program ( EAP ) commercial product available .</brief_summary>
	<brief_title>Sapropterin Expanded Access Program</brief_title>
	<detailed_description>The sapropterin EAP ( SEAP ) open-label , multi-center program design provide access sapropterin dihydrochloride patient diagnose hyperphenylalaninemia due PKU . All patient confirm diagnosis hyperphenylalaninemia due PKU currently enrol clinical study sapropterin dihydrochloride meet requisite inclusion criterion meet exclusion criterion may eligible participate program . Eligible patient may receive sapropterin dihydrochloride participate program commercial drug available , however , program continue beyond 2 month product receive market approval FDA . During program , physician use clinical judgment ass whether patient responder sapropterin dihydrochloride . Participating physician measure blood Phe level baseline prior treatment least Day 7 Day 30 follow initiation treatment determine patient responder . A responder patient clinically significant reduction either absolute percent decrease blood phenylalanine level compare pre-treatment level . The recommended starting dose sapropterin dihydrochloride 20 mg/kg/day . Physicians treat patient sapropterin dihydrochloride able adjust dose within range 5 mg/kg/day 20 mg/kg/day warrant clinical judgment . Adverse event information collect ongoing fashion patient report AEs physician . Physicians ask patient information regard adverse event occur since last visit . An adverse event report form complete case send BioMarin .</detailed_description>
	<mesh_term>Phenylketonurias</mesh_term>
	<mesh_term>Verapamil</mesh_term>
	<criteria>1 . Patient hyperphenylalaninemia due PKU , rare serious disease 2 . Patient participate sapropterin dihydrochloride clinical study 3 . Patient old 8 year age 4 . Patient willing able provide write informed consent , case age 18 , provide write assent ( require ) write informed consent parent legal guardian 5 . If female child bear potential , patient negative urine pregnancy test within 24 hour prior enrollment ( female childbearing potential ) use adequate contraceptive method avoid pregnancy participate program 6 . Patient willing able comply program procedures 7 . Patient life United States 1 . Patient perceive unreliable unwilling comply program participation , age 18 , parent legal guardian perceive unreliable unwilling comply program participation 2 . Patient concurrent disease condition would interfere program participation safety 3 . Patient 8 year old young 4 . Patients eligible enrol PKU010 5 . Patient participate ongoing study sapropterin dihydrochloride 6 . Patient pregnant , breast feeding consider pregnancy 7 . Patient take levodopa</criteria>
	<gender>All</gender>
	<minimum_age>9 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2008</verification_date>
	<keyword>Phenylketonuria</keyword>
	<keyword>PKU</keyword>
	<keyword>Phenylketonurias</keyword>
	<keyword>Hyperphenylalaninaemia</keyword>
	<keyword>Hydroxylase Deficiency</keyword>
</DOC>